Tradeoffs in Patient Decision Making About Rectal Cancer Treatment: Benefits Compared to Quality Of Life.
Launched by SIR MORTIMER B. DAVIS - JEWISH GENERAL HOSPITAL · Jun 7, 2021
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is focused on understanding how patients with rectal cancer make decisions about their treatment options. It will explore what patients prefer when it comes to treatment, considering their personal backgrounds and the thought processes that influence their choices. The study will look at three common treatment options: standard care, non-operative management, and surgery. To participate, patients need to be newly diagnosed with operable rectal cancer, at least 18 years old, and able to complete online questionnaires. Doctors who treat rectal cancer can also join the study.
Participants can expect to fill out two questionnaires that will help researchers understand their preferences for treatment and how these choices relate to their quality of life. The trial is currently recruiting participants, and it’s important to note that those with advanced cancer, recurrent tumors, or difficulties with communication in French or English are not eligible to join. This study aims to give valuable insights that can help improve treatment decisions for future patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Group A
- • New rectal cancer patient
- • Operable patients
- • Capable adults older than 18 years of age
- • Capacity to sign a consent form
- • Capacity to answer questionnaires on an online platform Group B
- • Treating physician specialists
- • Capacity to sign a consent form
- • Capacity to answer questionnaires on an online platform
- Exclusion Criteria:
- Group A:
- • Patient unable to sign a consent form
- • Patients with metastasis
- • Recurrent tumours
- • Inability to answer questionnaires on an online platform
- • Inability to communicate in french or english
- Group B:
- • Participant unable to sign a consent form
- • Inability to answer questionnaires on an online platform
About Sir Mortimer B. Davis Jewish General Hospital
Sir Mortimer B. Davis – Jewish General Hospital is a leading academic medical center located in Montreal, Canada, renowned for its commitment to advancing healthcare through innovative research and clinical trials. As a prominent sponsor of clinical research, the hospital integrates cutting-edge scientific inquiry with comprehensive patient care, focusing on a range of medical disciplines to enhance treatment outcomes and improve patient quality of life. With a strong emphasis on collaboration, ethics, and community engagement, the hospital strives to foster a research environment that promotes discovery and translates findings into effective therapeutic solutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Montreal, Quebec, Canada
Patients applied
Trial Officials
Té Vuong
Principal Investigator
Lady Davis Institute - JGH
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials